Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-Transplant Relapsed AML.
Post-transplant relapsed acute myeloid leukemia (AML) carries a dismal prognosis. Whether gemtuzumab ozogamicin (GO)-containing salvage strategies can achieve sufficient disease control to facilitate second (2nd) allo-HSCT remains unclear. We retrospectively analyzed 34 patients with CD33-positive AML treated with GO-c...